Preprint · CC-BY
via OpenAlex
Nicotinamide mononucleotide treatment increases NAD+ levels in an iPSC Model of Parkinson’s Disease but does not impact sirtuin activity
Brett Fulleylove-Krause, Samantha L. Sison, Allison D. Ebert
Research Square · 2020
Abstract
Abstract Objectives: Parkinson’s disease (PD) is a common neurodegenerative disorder caused by the loss of dopaminergic neurons in the substantia nigra. Although the underlying mechanisms of dopaminergic neuron loss is not fully understood, evidence suggests mitochondrial malfunction as a key contributor to disease pathogenesis. We previously found that human PD patient stem cell-derived dopaminergic neurons exhibit reduced nicotinamide adenine dinucleotide (NAD+) levels and reduce activity of sirtuins, a group of NAD+-dependent deacetylase enzymes that participate in the regulation of mitochondrial function, energy production, and cell survival. Thus, here we tested whether treatment of PD stem cell-derived dopaminergic neurons with nicotinamide mononucleotide (NMN), an NAD+ precursor, could increase NAD+ levels and improve sirtuin activity. Results: We treated PD iPSC-derived dopaminergic neurons with NMN and found that NAD+ levels did increase. The deacetylase activity of sirtuin (SIRT) 2 was improved with NMN treatment, but NMN had no impact on deacetylase activity of SIRT 1 or 3. These results suggest that NMN can restore NAD+ levels and SIRT 2 activity, but that additional mechanisms are involved SIRT 1 and 3 dysregulation in PD dopaminergic neurons.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.21203/rs.3.rs-43558/v1
- Canonical
- link ↗
- Fetched
- 2026-10-09 MST
Cite this
APA
Fulleylove-Krause, B., Sison, S.L., & Ebert, A.D. (2020). Nicotinamide mononucleotide treatment increases NAD+ levels in an iPSC Model of Parkinson’s Disease but does not impact sirtuin activity. <em>Research Square</em>. https://doi.org/10.21203/rs.3.rs-43558/v1
Vancouver
Fulleylove-Krause B, Sison SL, Ebert AD. Nicotinamide mononucleotide treatment increases NAD+ levels in an iPSC Model of Parkinson’s Disease but does not impact sirtuin activity. Research Square. 2020. doi:10.21203/rs.3.rs-43558/v1.
BibTeX
@unpublished{brett2020Nicoti,
title = {Nicotinamide mononucleotide treatment increases NAD+ levels in an iPSC Model of Parkinson’s Disease but does not impact sirtuin activity},
author = {Brett Fulleylove-Krause and Samantha L. Sison and Allison D. Ebert},
journal = {Research Square},
year = {2020},
doi = {10.21203/rs.3.rs-43558/v1},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
bioRxiv (Cold Spring Harbor Laboratory) 2020
Preprint · CC-BY
Nicotinamide mononucleotide treatment increases NAD+ levels in an iPSC Model of Parkinson’s Disease
Cell Reports 2018
Open access · CC-BY
The NAD+ Precursor Nicotinamide Riboside Rescues Mitochondrial Defects and Neuronal Loss in iPSC and Fly Models of Parkinson’s Disease
Advanced Functional Materials 2025
Open access · OA
Nanopore Identification of Nicotinamide Adenine Nucleotide and Its Derivatives
Ageing Research Reviews 2014
Open access · CC-BY
Ageing and Parkinson's disease: Why is advancing age the biggest risk factor?
Frontiers in Neurology 2026
Open access · CC-BY
NAD+ signaling in Parkinson's disease: molecular mechanisms and therapeutic perspectives
Biotechnology Journal 2024
Open access · CC-BY